Vietnam's Highest-Level Registration: A New Benchmark for Southeast Asian Expansion
Medgen Life Science (Shenzhen) Co., Ltd. has announced that its independently developed BoneSwift™ pre-filled injectable bone filling material has successfully obtained Class D medical device registration from Vietnam's Ministry of Health (MOH). This follows the product's earlier approval under China's NMPA as a Class III medical device.
This achievement marks BoneSwift™'s official market access qualification in Vietnam and sets a new benchmark for Chinese medical device companies expanding into Southeast Asia.
Class D Registration: Vietnam's Highest Risk Classification
Vietnam is one of the most dynamic and high-growth medical device markets in Southeast Asia. Class D medical device registration represents the highest risk classification in Vietnam's regulatory system, with the most complex and stringent approval process and extremely high requirements for the professionalism, completeness, and compliance of application materials.
The successful approval of Medgen's injectable bone filling material demonstrates the team's expertise and commitment to pursuing legally compliant global market registrations.
Core Product Advantages
As the first flagship product in Medgen's global market expansion strategy, this injectable bone filling material is derived from natural porcine cancellous bone. Key product strengths include:
- Natural trabecular bone structure retained from the source material, facilitating rapid cell attachment and proliferation
- Biomimetic microenvironment simulating human skeletal conditions with excellent osteoinductive properties to accelerate bone healing
- Pre-filled injectable format enabling direct injection during clinical use without on-site preparation
- Superior malleability allowing free shaping to efficiently reduce surgical time
The product holds broad application prospects and clinical demand in the global orthopedic market.
Global Strategic Positioning
The Southeast Asian market is a key component of Medgen's global strategy. This approval represents a major milestone in launching Medgen's internationalization journey. It brings high-quality Chinese medical solutions to Vietnamese hospitals and patients, rapidly enhances Medgen's core competitiveness and influence in the international medical market, and lays a compliant foundation for the company's global healthcare business expansion.
Looking ahead, Medgen will continue to uphold its founding mission of "from medicine, for medicine," deepening its commitment to independent R&D and innovation in natural regenerative medical materials across orthopedics, medical aesthetics, dentistry, and sports medicine. The company will simultaneously pursue regulatory market access across additional countries, actively expanding its international presence to bring outstanding Chinese medical technologies to the world for the benefit of patients globally.